STOCK TITAN

Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has been officially included in the Nasdaq Biotechnology Index effective December 20, 2021. This inclusion aims to enhance the company's visibility and attract investors as it continues to advance its AAV-based gene therapy pipeline focused on treating monogenic diseases of the CNS. The Nasdaq Biotechnology Index tracks biotechnology and pharmaceutical securities that meet specific eligibility criteria, reflecting Taysha's commitment to developing curative treatments for patients.

Positive
  • Inclusion in the Nasdaq Biotechnology Index is expected to increase visibility and investor awareness.
  • The company has a broad pipeline focused on AAV-based gene therapies for CNS diseases.
Negative
  • None.

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021.

“We are pleased to announce Taysha’s inclusion in the Nasdaq Biotechnology Index,” said RA Session II, President, Founder and CEO of Taysha. “As we continue to advance our broad pipeline and execute on our near-term clinical and regulatory milestones, inclusion in this index will enhance our visibility and expand awareness of our story with investors.”

The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:

Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies

FAQ

When was Taysha Gene Therapies added to the Nasdaq Biotechnology Index?

Taysha Gene Therapies was added to the Nasdaq Biotechnology Index effective December 20, 2021.

What is the significance of the Nasdaq Biotechnology Index for Taysha (TSHA)?

Inclusion in the Nasdaq Biotechnology Index enhances Taysha's visibility and expands investor awareness.

What type of therapies does Taysha Gene Therapies focus on?

Taysha focuses on developing AAV-based gene therapies for monogenic diseases of the central nervous system.

What are the criteria for inclusion in the Nasdaq Biotechnology Index?

Companies must meet minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria.

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Stock Data

304.34M
204.94M
17.54%
78.21%
10.1%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DALLAS